By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Immunology. According to news reporting originating in Solna, Sweden, by NewsRx journalists, research stated, "One of the issues in using polyclonal antibodies is the limited amount of reagent available from an immunisation, leading to batch-to-batch variation and difficulties in obtaining the same antibody performance when the same antigen is re-immunised into several separate animals. This led to the development of hybridoma technology allowing, at least theoretically, for an unlimited production of a specific binder."
The news reporters obtained a quote from the research from the KTH Royal Institute of Technology, "Nevertheless, polyclonal antibodies are widely used in research and diagnostics and there exists a need for robust methods to convert a polyclonal antibody with good binding performance into a renewable monoclonal with identical or similar binding specificity. Here we have used precise information regarding the functional recognition sequence (epitope) of a rabbit polyclonal antibody with attractive binding characteristics as the basis for generation of a renewable mouse monoclonal antibody. First, the original protein fragment antigen was used for immunisation and generation of mouse hybridoma, without obtaining binders to the same epitope region. Instead a peptide designed using the functional epitope and structural information was synthesised and used for hybridoma production. Several of the monoclonal antibodies generated were found to have similar binding characteristics to those of the original polyclonal antibody."
According to the news reporters, the research concluded: "These monoclonal antibodies detected native HER2 on cell lines and were also able to stain HER2 in immunohistochemistry using xenografted mice, as well as human normal and cancer tissues."
For more information on this research see: Generation of HER2 monoclonal antibodies using epitopes of a rabbit polyclonal antibody. New Biotechnology, 2014;31(1):35-43. New Biotechnology can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; New Biotechnology - www.elsevier.com/wps/product/cws_home/713354)
Our news correspondents report that additional information may be obtained by contacting F.J. Hu, KTH Royal Inst Technol, Sci Life Lab, SE-17165 Solna, Sweden. Additional authors for this research include M. Uhlen and J. Rockberg (see also Immunology).
Keywords for this news article include: Antigens, Solna, Sweden, Europe, Epitopes, Immunology, Blood Proteins, Immunoglobulins, Serum Globulins, Monoclonal Antibodies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC